Covid-19 Impact on High Performance Active Pharmaceutical Ingredients (HPAPI) Market , Global Research Reports 2020-2021

1.2 Market Segmentation

1.3 Research Objectives

1.4 Research Methodology

1.4.1 Research Process

1.4.2 Data Triangulation

1.4.3 Research Approach

1.4.4 Base Year

1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.5.2 Covid-19 Impact: Commodity Prices Indices

1.5.3 Covid-19 Impact: Global Major Government Policy

1.6 The Covid-19 Impact on High Performance Active Pharmaceutical Ingredients (HPAPI) Industry

1.7 COVID-19 Impact: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Trends

2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Market Size Analysis

2.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Business Impact Assessment - COVID-19

2.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026

2.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026

2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Market Size 2020-2021

2.3 COVID-19-Driven Market Dynamics and Factor Analysis

2.3.1 Drivers

2.3.2 Restraints

2.3.3 Opportunities

2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

3.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Market Size by Manufacturers, 2019 VS 2020

3.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Factory Price by Manufacturers

3.3 Location of Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturing Factories and Area Served

3.4 Date of Key Manufacturers Enter into High Performance Active Pharmaceutical Ingredients (HPAPI) Market

3.5 Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Product Offered

3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on High Performance Active Pharmaceutical Ingredients (HPAPI) Segments, By Type

4.1 Introduction

1.4.1 Synthetic Ingredients

1.4.2 Biological Ingredients

1.4.3 Others

4.2 By Type, Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021

4.2.1 By Type, Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Type, 2020-2021

4.2.2 By Type, Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price, 2020-2021

5 Impact of Covid-19 on High Performance Active Pharmaceutical Ingredients (HPAPI) Segments, By Application

5.1 Overview

5.5.1 Oncology

5.5.2 Glaucoma

5.5.3 Anti-diabetic

5.5.4 Cardiovascular

5.5.5 Musculoskeletal

5.5.6 Hormonal

5.5.7 Others

5.2 By Application, Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021

5.2.1 By Application, Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Application, 2019-2021

5.2.2 By Application, Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price, 2020-2021

6 Geographic Analysis

6.1 Introduction

6.2 North America

6.2.1 Macroeconomic Indicators of US

6.2.2 US

6.2.3 Canada

6.3 Europe

6.3.1 Macroeconomic Indicators of Europe

6.3.2 Germany

6.3.3 France

6.3.4 UK

6.3.5 Italy

6.4 Asia-Pacific

6.4.1 Macroeconomic Indicators of Asia-Pacific

6.4.2 China

6.4.3 Japan

6.4.4 South Korea

6.4.5 India

6.4.6 ASEAN

6.5 Rest of World

6.5.1 Latin America

6.5.2 Middle East and Africa

7 Company Profiles

7.1 Bristol-Myers Squibb

7.1.1 Bristol-Myers Squibb Business Overview

7.1.2 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.1.3 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.1.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments

7.2 Novartis

7.2.1 Novartis Business Overview

7.2.2 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.2.3 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.2.4 Novartis Response to COVID-19 and Related Developments

7.3 Sanofi Aventis

7.3.1 Sanofi Aventis Business Overview

7.3.2 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.3.3 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.3.4 Sanofi Aventis Response to COVID-19 and Related Developments

7.4 Pfizer

7.4.1 Pfizer Business Overview

7.4.2 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.4.3 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.4.4 Pfizer Response to COVID-19 and Related Developments

7.5 Lonza

7.5.1 Lonza Business Overview

7.5.2 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.5.3 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.5.4 Lonza Response to COVID-19 and Related Developments

7.6 Novasep

7.6.1 Novasep Business Overview

7.6.2 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.6.3 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.6.4 Novasep Response to COVID-19 and Related Developments

7.7 Hospira

7.7.1 Hospira Business Overview

7.7.2 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.7.3 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.7.4 Hospira Response to COVID-19 and Related Developments

7.8 BASF

7.8.1 BASF Business Overview

7.8.2 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.8.3 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.8.4 BASF Response to COVID-19 and Related Developments

7.9 Merck

7.9.1 Merck Business Overview

7.9.2 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.9.3 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.9.4 Merck Response to COVID-19 and Related Developments

7.10 Bayer

7.10.1 Bayer Business Overview

7.10.2 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.10.3 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.10.4 Bayer Response to COVID-19 and Related Developments

7.11 Teva Pharmaceuticals

7.11.1 Teva Pharmaceuticals Business Overview

7.11.2 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.11.3 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.11.4 Teva Pharmaceuticals Response to COVID-19 and Related Developments

7.12 Boehringer Ingelheim

7.12.1 Boehringer Ingelheim Business Overview

7.12.2 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Production and Revenue, 2020

7.12.3 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction

7.12.4 Boehringer Ingelheim Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

8.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Supply Chain Analysis

8.1.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Supply Chain Analysis

8.1.2 Covid-19 Impact on High Performance Active Pharmaceutical Ingredients (HPAPI) Supply Chain

8.2 Distribution Channels Analysis

8.2.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Distribution Channels

8.2.2 Covid-19 Impact on High Performance Active Pharmaceutical Ingredients (HPAPI) Distribution Channels

8.2.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Distributors

8.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Customers

9 Key Findings

10 Appendix

10.1 About Us

10.2 Disclaimer

Table 1. Overview of the World Economic Outlook Projections

Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 7. Covid-19 Impact: Global Major Government Policy

Table 8. The Covid-19 Impact on High Performance Active Pharmaceutical Ingredients (HPAPI) Assessment

Table 9. COVID-19 Impact: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Trends

Table 10. COVID-19 Impact Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size

Table 11. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K MT)

Table 12. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/MT)

Table 13. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Market Size, 2020 (US$ Million) & (K MT)

Table 14. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)

Table 15. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K MT)

Table 16. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Growth Drivers

Table 17. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Restraints

Table 18. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Opportunities

Table 19. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Challenges

Table 20. Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Quarterly Revenue, 2019 VS 2020 (US$ Million)

Table 21. Top Manufacturers, High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019 (K MT) & (US$ Million)

Table 22. High Performance Active Pharmaceutical Ingredients (HPAPI) Factory Price by Manufacturers 2020 (USD/MT)

Table 23. Location of Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturing Plants

Table 24. Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Market Served

Table 25. Date of Key Manufacturers Enter into High Performance Active Pharmaceutical Ingredients (HPAPI) Market

Table 26. Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Product Type

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Type, 2020, (US$ Million)

Table 29. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Type, 2020 (K MT)

Table 30. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price: by Type, 2020-2021 (USD/MT)

Table 31. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Application: 2020-2021 (US$ Million)

Table 32. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Application, 2020-2021 (K MT)

Table 33. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price: by Application, 2020-2021 (USD/MT)

Table 34. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Region, 2019-2021 (US$ Million)

Table 35. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Region, 2019-2021 (K MT)

Table 36. By Country, North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million)

Table 37. By Country, North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (K MT)

Table 38. US High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 39. Canada High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)

Table 41. By Country, Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million)

Table 42. By Country, Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (K MT)

Table 43. Germany High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 44. France High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 45. UK High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 46. Italy High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)

Table 48. By Region, Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million)

Table 49. By Region, Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (K MT)

Table 50. China High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 51. Japan High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 52. South Korea High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 53. India High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 54. ASEAN High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 55. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 56. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, 2019-2021 (US$ Million) & (K MT)

Table 57. Bristol-Myers Squibb Business Overview

Table 58. Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 59. Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 60. Bristol-Myers Squibb Response to COVID-19 and Related Developments

Table 61. Novartis Business Overview

Table 62. Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 63. Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 64. Novartis Response to COVID-19 and Related Developments

Table 65. Sanofi Aventis Business Overview

Table 66. Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 67. Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 68. Sanofi Aventis Response to COVID-19 and Related Developments

Table 69. Pfizer Business Overview

Table 70. Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 71. Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 72. Pfizer Response to COVID-19 and Related Developments

Table 73. Lonza Business Overview

Table 74. Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 75. Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 76. Lonza Response to COVID-19 and Related Developments

Table 77. Novasep Business Overview

Table 78. Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 79. Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 80. Novasep Response to COVID-19 and Related Developments

Table 81. Hospira Business Overview

Table 82. Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 83. Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 84. Hospira Response to COVID-19 and Related Developments

Table 85. BASF Business Overview

Table 86. BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 87. BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 88. BASF Response to COVID-19 and Related Developments

Table 89. Merck Business Overview

Table 90. Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 91. Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 92. Merck Response to COVID-19 and Related Developments

Table 93. Bayer Business Overview

Table 94. Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 95. Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 96. Bayer Response to COVID-19 and Related Developments

Table 97. Teva Pharmaceuticals Business Overview

Table 98. Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 99. Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 100. Teva Pharmaceuticals Response to COVID-19 and Related Developments

Table 101. Boehringer Ingelheim Business Overview

Table 102. Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 103. Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Product

Table 104. Boehringer Ingelheim Response to COVID-19 and Related Developments

Table 105. High Performance Active Pharmaceutical Ingredients (HPAPI) Distributors List

Table 106. High Performance Active Pharmaceutical Ingredients (HPAPI) Customers List

Table 107. Covid-19 Impact on High Performance Active Pharmaceutical Ingredients (HPAPI) Customers

List of Figures

Figure 1. High Performance Active Pharmaceutical Ingredients (HPAPI) Product Picture

Figure 2. High Performance Active Pharmaceutical Ingredients (HPAPI) Market Segmentation

Figure 3. Research Objectives

Figure 4. Research Process

Figure 5. Data Triangulation

Figure 6. Research Approach

Figure 7. Commodity Prices-Metals Price Indices

Figure 8. Commodity Prices- Precious Metal Price Indices

Figure 9. Commodity Prices- Agricultural Raw Material Price Indices

Figure 10. Commodity Prices- Food and Beverage Price Indices

Figure 11. Commodity Prices- Fertilizer Price Indices

Figure 12. Commodity Prices- Energy Price Indices

Figure 13. G20+: Economic Policy Responses to COVID-19

Figure 14. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)

Figure 15. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)

Figure 16. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Quarterly Growth, 2020-2021 (%)

Figure 17. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Market Share by Type, 2019 VS 2020 (%)

Figure 18. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Market Share by Application, 2019 VS 2020 (%)

Figure 19. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Market Share by Region, 2019 VS 2020 (%)

Figure 20. United States Composite PMI and GDP

Figure 21. Eurozone Composite PMI and GDP

Figure 22. Eurozone Core v. Periphery PMI Output Indices

Figure 23. Core v. Periphery PMI Employment Indices

Figure 24. UK Composite PMI and GDP

Figure 25. Caixin China Composite Output Index

Figure 26. Caixin China General Services Business Activity Index

Figure 27. Japan Composite Output Index

Figure 28. South Korea Manufacturing PMI

Figure 29. India Composite Output Index

Figure 30. ASEAN Manufacturing PMI

Figure 31. By Region, Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Market Share, 2019-2021